<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02179320</url>
  </required_header>
  <id_info>
    <org_study_id>HC-GDOR-MIOFASCIAL</org_study_id>
    <nct_id>NCT02179320</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy and Neurological Effects of Dry Needling in the Treatment of Myofascial Pain Syndrome</brief_title>
  <official_title>Evaluation of the Efficacy and Neurological Effects of Dry Needling in the Treatment of Myofascial Pain Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      AIM OF INVESTIGATION: To evaluate in a prospective, randomized, sham-controlled study the
      pattern of analgesic efficacy of trigger point dry needling in Myofascial Pain Syndrome (MPS)
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be performed in patients with shoulder pain due to excess of nociception
      associated with chronic Myofascial Pain Syndrome in asymmetrical unilateral trapezius muscle
      trigger points.

      Patients will be randomly assigned to two treatment arms: Active (A) (n=20) and Sham (S)
      (n=21). Group A will receive actual treatment with trigger point dry needling. Group S will
      receive a sham treatment, with the needle inserted superficially in the skin, without
      reaching the muscle underneath it.

      The duration and pain elicited during active and sham dry needling will be controlled for.
      Patients will be evaluated one week before needling (D-7), on the day of dry needling (D0)
      and seven days after the procedure (D+7).

      Patients will fill out the Brazilian version of the Douleur Neuropathique 4, Beck Depression
      Inventory, Brief Pain Inventory (BPI), McGill Pain Questionnaire-SF (SFMPQ), Hospital Anxiety
      and Depression Scale and Global Impression of Change, and also a 14-day Carnet to more
      accurately evaluate their daily pain before and after the treatment.

      For the evaluation of neurologic changes, we will evaluate local hyperalgesia, tactile,
      mechanical, static and thermal sensitivity with thermal quantitative sensorial testing (TQS),
      and also mapping of the painful area, before and after treatment in both D0 and D+7.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2014</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Analgesic effects of dry needling</measure>
    <time_frame>Within the first 7 days after treatment</time_frame>
    <description>Maximum, average and lowest pain will be evaluated daily 7 days before the treatment, on the day of the treatment, and also 7 days after the treatment is done.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neurologic effects of dry needling</measure>
    <time_frame>Within the first 7 days after treatment</time_frame>
    <description>Tactile, mechanical, static and thermal sensitivity will be evaluated with thermal quantitative sensorial testing, as well as hyperalgesia. The painful area will also be mapped to compara before and after treatment results.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Myofascial Pain Syndrome</condition>
  <arm_group>
    <arm_group_label>Dry needling</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dry needling for myofascial pain syndrome, in the trapezius muscle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham needling</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Superficial dry needling in the trapezius muscle</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Dry needling</intervention_name>
    <description>Dry needling of the painful muscles, with an acupuncture needle 0,25 x 40mm</description>
    <arm_group_label>Dry needling</arm_group_label>
    <arm_group_label>Sham needling</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>acupuncture needle 0,25 x 40mm</intervention_name>
    <arm_group_label>Dry needling</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Assymetric shoulder pain (VAS on painful side : VAS on non painful side &gt; 2:1)

          -  Pain due to unilateral Myofascial Pain Syndrome of the trapezius muscle.

          -  Chronic pain, with duration of at least 3 months and VAS &gt; 40/100

          -  Patients with pain at least 4 days in a week

          -  Patients without neurological pain, as in DN4 score less than 4

          -  Age over 18 years

          -  Patients with stable drug treatment over at least 15 days, without any acute
             pharmacological changes during the study

          -  Patients who read, understood and signed the Free and Clarified Consent Term

        Exclusion Criteria:

          -  Patients with major depression, according to DSM-IV criteria

          -  History of bipolar mood disorder, panic syndrome or psychosis

          -  Intermittent pain history

          -  Refusal to sing the Consent Term

          -  Patients not able to attend all the follow-ups

          -  Patients with another pain syndrome in shoulders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel C Andrade, M.D., P.h.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juliana T Toma, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Irina Raicher, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manoel J Teixeira, M.D., P.h.D.</last_name>
    <role>Study Director</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Helena H Kaziyama, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>05403-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Yap EC. Myofascial pain--an overview. Ann Acad Med Singapore. 2007 Jan;36(1):43-8. Review.</citation>
    <PMID>17285185</PMID>
  </reference>
  <reference>
    <citation>Gerwin RD. Classification, epidemiology, and natural history of myofascial pain syndrome. Curr Pain Headache Rep. 2001 Oct;5(5):412-20. Review.</citation>
    <PMID>11560806</PMID>
  </reference>
  <reference>
    <citation>Ga H, Choi JH, Park CH, Yoon HJ. Dry needling of trigger points with and without paraspinal needling in myofascial pain syndromes in elderly patients. J Altern Complement Med. 2007 Jul-Aug;13(6):617-24.</citation>
    <PMID>17718644</PMID>
  </reference>
  <reference>
    <citation>Cummings TM, White AR. Needling therapies in the management of myofascial trigger point pain: a systematic review. Arch Phys Med Rehabil. 2001 Jul;82(7):986-92. Review.</citation>
    <PMID>11441390</PMID>
  </reference>
  <reference>
    <citation>McCain GA, Bell DA, Mai FM, Halliday PD. A controlled study of the effects of a supervised cardiovascular fitness training program on the manifestations of primary fibromyalgia. Arthritis Rheum. 1988 Sep;31(9):1135-41.</citation>
    <PMID>3048273</PMID>
  </reference>
  <reference>
    <citation>Giamberardino MA. Referred muscle pain/hyperalgesia and central sensitisation. J Rehabil Med. 2003 May;(41 Suppl):85-8. Review.</citation>
    <PMID>12817663</PMID>
  </reference>
  <reference>
    <citation>Ge HY, Fernández-de-las-Peñas C, Arendt-Nielsen L. Sympathetic facilitation of hyperalgesia evoked from myofascial tender and trigger points in patients with unilateral shoulder pain. Clin Neurophysiol. 2006 Jul;117(7):1545-50. Epub 2006 Jun 5.</citation>
    <PMID>16737848</PMID>
  </reference>
  <reference>
    <citation>Hong CZ, Simons DG. Pathophysiologic and electrophysiologic mechanisms of myofascial trigger points. Arch Phys Med Rehabil. 1998 Jul;79(7):863-72. Review.</citation>
    <PMID>9685106</PMID>
  </reference>
  <reference>
    <citation>Hong CZ. Treatment of myofascial pain syndrome. Curr Pain Headache Rep. 2006 Oct;10(5):345-9. Review.</citation>
    <PMID>16945250</PMID>
  </reference>
  <reference>
    <citation>Giamberardino MA, Affaitati G, Fabrizio A, Costantini R. Myofascial pain syndromes and their evaluation. Best Pract Res Clin Rheumatol. 2011 Apr;25(2):185-98. doi: 10.1016/j.berh.2011.01.002. Review.</citation>
    <PMID>22094195</PMID>
  </reference>
  <reference>
    <citation>Skootsky SA, Jaeger B, Oye RK. Prevalence of myofascial pain in general internal medicine practice. West J Med. 1989 Aug;151(2):157-60.</citation>
    <PMID>2788962</PMID>
  </reference>
  <reference>
    <citation>SOLA AE, RODENBERGER ML, GETTYS BB. Incidence of hypersensitive areas in posterior shoulder muscles; a survey of two hundred young adults. Am J Phys Med. 1955 Dec;34(6):585-90.</citation>
    <PMID>13268620</PMID>
  </reference>
  <reference>
    <citation>Hong CZ. Lidocaine injection versus dry needling to myofascial trigger point. The importance of the local twitch response. Am J Phys Med Rehabil. 1994 Jul-Aug;73(4):256-63.</citation>
    <PMID>8043247</PMID>
  </reference>
  <reference>
    <citation>Ge HY, Fernández-de-Las-Peñas C, Madeleine P, Arendt-Nielsen L. Topographical mapping and mechanical pain sensitivity of myofascial trigger points in the infraspinatus muscle. Eur J Pain. 2008 Oct;12(7):859-65. doi: 10.1016/j.ejpain.2007.12.005. Epub 2008 Jan 18.</citation>
    <PMID>18203637</PMID>
  </reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2014</study_first_submitted>
  <study_first_submitted_qc>June 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2014</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myofascial Pain Syndrome</keyword>
  <keyword>Dry needling</keyword>
  <keyword>Clinical Trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Somatoform Disorders</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
    <mesh_term>Fibromyalgia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

